In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

International Expansion Stays On Nichi-Iko’s Agenda As Sagent Struggles

Executive Summary

Japan’s Nichi-Iko is looking to grow its overseas sales by around a fifth each year, even as its North American injectables affiliate Sagent struggles to move forward and to make a profit.

You may also be interested in...



Nichi-Iko And Eisai Expand Alliance To China

Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.

Sagent Slides To A Loss, Dragging Down Nichi-Iko’s Margin

An operating loss recorded by its US Sagent affiliate depressed Nichi-Iko’s group operating margin to just 3.7%, even though the Japanese generics specialist’s turnover increased by a tenth on strong domestic generics demand.

Nichi-Iko aids Elmed under deal with Eisai

Nichi-Iko has started promoting the value-added portfolio of Eisai’s Elmed in Japan under a strategic alliance struck earlier this year that also includes Nichi-Iko acquiring all shares in Elmed by 1 April 2019. As part of the “phased acquisition” (Generics bulletin, 6 April 2018, page 3), Nichi-Iko said it had by 1 October acquired a third of stocks in Elmed for a total of ¥5.47 billion (US$48.7 million).

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel